Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05039801CT.gov IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uterine Corpus Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipn 60090 (this asset) | M.D. Anderson Cancer Center | P1 | CC · 43 |
| Carboplatin | City of Hope Medical Center | P3 | BB |
| Cabozantinib | M.D. Anderson Cancer Center | P2 | BB |
| Irinotecan | M.D. Anderson Cancer Center | P2 | BB |
| Palbociclib | Pamela Munster | P2 | B |
| Capivasertib | M.D. Anderson Cancer Center | P2 | B |
| Olaparib | National Cancer Institute (NCI) | P2 | B |
| Sapanisertib | National Cancer Institute (NCI) | P2 | B |
| Nivolumab | M.D. Anderson Cancer Center | P2 | B |
+42 more in the Uterine Corpus Cancer cohort
Other indications for Ipn 60090
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Head And Neck Squamous Cell Carcinoma | — | P1 | CC · 43 |
| Endometrial Carcinoma | — | P1 | CC · 43 |
| Ovarian Clear Cell Adenocarcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipn 60090 in Uterine Corpus Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipn-60090-uterine-corpus-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →